AU2015330642B2 - Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis - Google Patents

Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Download PDF

Info

Publication number
AU2015330642B2
AU2015330642B2 AU2015330642A AU2015330642A AU2015330642B2 AU 2015330642 B2 AU2015330642 B2 AU 2015330642B2 AU 2015330642 A AU2015330642 A AU 2015330642A AU 2015330642 A AU2015330642 A AU 2015330642A AU 2015330642 B2 AU2015330642 B2 AU 2015330642B2
Authority
AU
Australia
Prior art keywords
cooh
osteoporosis
bone
subject
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015330642A
Other languages
English (en)
Other versions
AU2015330642A1 (en
Inventor
Lyne Gagnon
Brigitte Grouix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal Biosciences Ltd
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Publication of AU2015330642A1 publication Critical patent/AU2015330642A1/en
Application granted granted Critical
Publication of AU2015330642B2 publication Critical patent/AU2015330642B2/en
Assigned to PROMETIC PHARMA SMT LIMITED reassignment PROMETIC PHARMA SMT LIMITED Amend patent request/document other than specification (104) Assignors: PROMETIC PHARMA SMT LIMITED
Assigned to Liminal Biosciences Limited reassignment Liminal Biosciences Limited Request to Amend Deed and Register Assignors: PROMETIC PHARMA SMT LIMITED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015330642A 2014-10-10 2015-10-08 Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Ceased AU2015330642B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062660P 2014-10-10 2014-10-10
US62/062,660 2014-10-10
PCT/CA2015/000530 WO2016054725A1 (en) 2014-10-10 2015-10-08 Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Publications (2)

Publication Number Publication Date
AU2015330642A1 AU2015330642A1 (en) 2017-05-11
AU2015330642B2 true AU2015330642B2 (en) 2019-07-04

Family

ID=55652426

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015330642A Ceased AU2015330642B2 (en) 2014-10-10 2015-10-08 Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis

Country Status (22)

Country Link
US (1) US10925846B2 (enExample)
EP (1) EP3204000B1 (enExample)
JP (1) JP6700638B2 (enExample)
KR (1) KR20170066613A (enExample)
CN (1) CN106999459B (enExample)
AR (1) AR102247A1 (enExample)
AU (1) AU2015330642B2 (enExample)
BR (1) BR112017007386A2 (enExample)
CA (1) CA2963358C (enExample)
DK (1) DK3204000T3 (enExample)
ES (1) ES2794782T3 (enExample)
IL (1) IL251409B (enExample)
MX (1) MX376880B (enExample)
MY (1) MY187511A (enExample)
PH (1) PH12017500636A1 (enExample)
PL (1) PL3204000T3 (enExample)
PT (1) PT3204000T (enExample)
RU (1) RU2712027C2 (enExample)
SG (1) SG11201702810TA (enExample)
TW (1) TWI723962B (enExample)
UY (1) UY36355A (enExample)
WO (1) WO2016054725A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124662A1 (en) * 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2777629C (en) * 2009-10-14 2018-02-13 The Governors Of The University Of Alberta Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof
US20130225683A1 (en) * 2010-10-27 2013-08-29 Prometic Biosciences Inc. Compounds and Pharmaceutical Compositions for Uses in Diabetes
PH12013500763B1 (en) * 2010-10-27 2018-07-04 Prometic Pharma Smt Ltd Phenylketone carboxylate compounds and pharmaceutical uses thereof
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
WO2014138372A1 (en) * 2013-03-06 2014-09-12 Primavera Biosciences, Inc. Composition and method for treating osteoarthritis
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124662A1 (en) * 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds

Also Published As

Publication number Publication date
CA2963358A1 (en) 2016-04-14
TW201618761A (zh) 2016-06-01
SG11201702810TA (en) 2017-05-30
IL251409B (en) 2020-08-31
UY36355A (es) 2016-06-01
CN106999459B (zh) 2020-07-10
PT3204000T (pt) 2020-05-06
RU2017116154A (ru) 2018-11-12
AU2015330642A1 (en) 2017-05-11
BR112017007386A2 (pt) 2018-01-23
PH12017500636A1 (en) 2017-09-25
ES2794782T3 (es) 2020-11-19
CN106999459A (zh) 2017-08-01
EP3204000B1 (en) 2020-01-08
TWI723962B (zh) 2021-04-11
DK3204000T3 (da) 2020-04-06
WO2016054725A1 (en) 2016-04-14
IL251409A0 (en) 2017-05-29
EP3204000A1 (en) 2017-08-16
AR102247A1 (es) 2017-02-15
JP6700638B2 (ja) 2020-05-27
US20190038580A1 (en) 2019-02-07
CA2963358C (en) 2023-03-07
RU2712027C2 (ru) 2020-01-27
MX376880B (es) 2025-03-07
PL3204000T3 (pl) 2020-07-27
KR20170066613A (ko) 2017-06-14
JP2017530179A (ja) 2017-10-12
MY187511A (en) 2021-09-24
US10925846B2 (en) 2021-02-23
EP3204000A4 (en) 2018-06-20
RU2017116154A3 (enExample) 2019-05-06
MX2017004735A (es) 2017-11-17

Similar Documents

Publication Publication Date Title
US11185521B2 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
EP2970089B1 (en) Substituted aromatic compounds
EP3443957A1 (en) Compounds and compositions for the treatment of cancer
BR112020013694A2 (pt) derivados de ácido 3-fenil-4-hexinôico como agonistas gpr40
WO2012060396A1 (ja) トランス－２－デセン酸誘導体及びこれを含有する医薬
AU2011320057B2 (en) Phenylketone carboxylate compounds and pharmaceutical uses thereof
CA2963358C (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
JP2004509121A (ja) チアゾリジン誘導体および抗真菌剤としてのその使用
HK1236419B (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1236419A1 (en) Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1236420A1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
HK1236420B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
TW201728332A (zh) 新穎雙膦酸化合物
JP2005035895A (ja) 高カルシウム血症および骨疾患治療剤
WO2024110592A1 (en) 4(rs)-4-f4-neuroprostane derivatives (4-f4t-neurop) and their use in treating ventilator induced diaphragmatic dysfunction and other diseases

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PROMETIC PHARMA SMT LIMITED

Free format text: FORMER NAME(S): PROMETIC PHARMA SMT LIMITED

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: LIMINAL BIOSCIENCES LIMITED

Free format text: FORMER NAME(S): PROMETIC PHARMA SMT LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired